3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
299
Carboplatin
229
Cisplatin
159
Gemcitabine
152
Paclitaxel
151
Pemetrexed
121
Bevacizumab
121
Docetaxel
106
Oxaliplatin
82
durvalumab
81
Nivolumab
81
Dexamethasone
80
atezolizumab
79
Fluorouracil
79
Cyclophosphamide
77
130-nm albumin-bound paclitaxel
73
Fulvestrant
72
Capecitabine
67
Injections
66
Cetuximab
64
Leucovorin
63
Rituximab
56
fludarabine
51
Lenalidomide
50
venetoclax
46
Prednisone
45
Letrozole
42
Irinotecan
42
enzalutamide
41
tislelizumab
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hizentra
×
90 days
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled